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Abstract  
BACKGROUND: Acute first-ever ischemic stroke (FIS) is a heterogeneous, polygenic disorder. The 
contribution of vascular genetic variants as inherited causes of ischemic stroke has remained 
controversial.  
AIM: To examine the association of genetic variants in vascular factors with the occurrence of FIS.  
MATERIAL AND METHODS: The current research was performed in a group of 39 patients with 
FIS (study group) and 102 healthy volunteers (control group). We analyzed the prevalence of 
vascular genetic variants in following genes: factor V, prothrombin, methylenetetrahydrofolate 
reductase (MTHFR), factor XIII, plasminogen activator 1, endothelial protein C receptor (EPCR), 
apolipoprotein B, apolipoprotein E, β-fibrinogen, human platelet antigen 1, angiotensin-converting 
enzyme (ACE), endothelial nitric oxide synthase (eNOS) and lymphotoxin alpha. 
 
RESULTS: It was found that heterozygous LTA 804C>A and FXIII V34L Leu/Leu were significantly 
more frequent in patients with FIS than in control group (p = 0.036 and p = 0.017, respectively). The 
frequency of FXIII V34L Val/Val was significantly lower in patients with FIS than in control group (p 
= 0.020). Other frequencies of vascular gene variants in patients with FIS and in control group were 
not significantly different. 
CONCLUSIONS: This is the first comprehensive study to present data indicating that polymorphism 
of vascular genes in the prevalence of acute FIS exists in the Albanian population from the 
Republic of Macedonia. Variations in these genes have been detected in patients with acute FIS, 
suggesting that their combination might act in a susceptible or protective manner in this Albanian 
population.
 
 
 
 
 
Introduction 
 
Ischemic stroke is a major public health 
problem with a heritable component to the risk of 
disease [1-3]. The last decade has been marked by 
initiatives aimed at raising awareness of the inherited 
predisposition to ischemic stroke. There has been an 
increase in studies that analysed polymorphic genes 
responsible for arterial and venous ischemic events. 
An increased understanding of genetics and 
molecular biology has fuelled this research and shed 
light on several genetic risk factors that may help to 
predict arterial events.
 
Most of the studies related to arterial 
thrombosis have actually involved patients with 
coronary syndromes [4], myocardial infarction [5] and 
events of the arterial circulatory system [6, 7], and 
they produced conflicting results. To date, most 
studies on the genetics of ischemic stroke have 
focused on candidate genes in a control group and 
unrelated cases. The causes of the majority of 
ischemic strokes include atherosclerotic, cardiogenic 
and lacunar (penetrating vessel) mechanisms [8]. 
Several animal and clinical studies clearly defined 
genetic predisposition to hereditary thrombophilia or 
atherosclerosis, in the case of atherosclerosis, and 
particularly, to the clinical expression of ischemic 
stroke [9]. Arteriosclerosis of the large vessels is the 
cause of cerebral infarction in almost half of all 
ischemic events [10]. Arteriosclerosis involves 
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numerous genes and some pathways thought to be 
involved in the development and rupture of 
atherosclerotic lesions [11]. 
Based on published data, the most common 
vascular genetic variations have been extensively 
studied, particularly in the following genes: factor V 
(FV), prothrombin (factor II; PTH), 
methylenetetrahydrofolate reductase (MTHFR), factor 
XIII (FXIII) [12, 13], plasminogen activator 1 (PAI-1) 
[14-18], endothelial protein C receptor (EPCR), 
apolipoprotein B (APOB) [19], apolipoprotein E 
(APOE) [20], β-fibrinogen (β-FG, FGB) [21], human 
platelet antigen 1 (HPA-1) [22, 23], angiotensin-
converting enzyme (ACE) [24, 25], endothelial nitric 
oxide synthase (eNOS) [26] and lymphotoxin alpha 
[27], which have been identified as risk factors for 
several diseases, such as arterial and/or venous 
thrombosis. However, with regard to testing for an 
association with susceptibility to ischemic stroke, 
study results are conflicting and the association is not 
always detected. Consequently, routine testing for 
polymorphisms associated with ischemic stroke is not 
part of the diagnostic protocol for elderly individuals, 
but the results are still debatable. 
This study is the first comprehensive study of 
the vascular gene variations associated with first-ever 
ischemic stroke in the Albanian population from the 
Republic of Macedonia. The purpose of this research 
was to examine the association of vascular gene 
variations in 13 genes and 17 genetic variants in 
patients with acute FIS and compare the frequencies 
in the patient and control groups. 
 
 
Material and Methods 
 
Sampling 
This study was a case-control study 
(comparative analytical study) carried out from 
September 2008 to August 2010. In total, 231 patients 
with FIS as a study group and 194 healthy volunteers 
as a control group were enrolled in the initial study. 
The inclusion criteria were consecutive patients 
admitted to the Neurology Department with confirmed 
diagnosis acute FIS, age ranging from 18 to 90 years, 
an absence of a history of stroke and completion of 
interview and analysis. All patients gave informed 
consent prior to participation in this study. The 
exclusion criteria were patients younger than 18 
years, patients, who had experienced an acute 
hemorrhagic stroke, a known malignancy, acute or 
chronic renal or failure or acute myocardial infarction 
and patients who had recent inflammatory or 
immunologic disease. Acute FIS was defined as a 
clinical syndrome on the basis of clinical symptoms 
and (a) recent infarct(s) in the clinically relevant area 
of the brain, using brain computed tomography (CT) 
and/or magnetic resonance imaging (MRI).  
Healthy controls that were free from 
cerebrovascular diseases were selected from among 
local residents, using the same exclusion criterion as 
for patients. Informed consent was obtained from all 
participants prior to conducting the study. The protocol 
of the study was reviewed and approved by the 
professional college at Clinical Hospital Tetovo (Nr.02-
1280/2, 02.07.2008) [28]. 
Within a study of the genetics of the 
Macedonian population, a detailed description of the 
study subjects and study design were performed as 
previously described [29, 30]. Briefly, after signed 
consent was given to obtain and store a DNA sample, 
212 subjects were recruited in total (stratified into 58 
healthy controls and 12 patients of Macedonian origin 
and 103 healthy controls and 39 patients of Albanian 
origin) all residents of Tetovo and its neighbouring 
region who met the study inclusion criteria to engage 
in the proposed national project over a 2-year period 
(2010–2012), examining gene variations associated 
with diseases of blood vessels in the Republic of 
Macedonia, which was originally designed as a 
prospective, nationwide, multicenter case-control 
study (ID 13-3589/1, 26.07.2010).  
Among others, the objectives were to 
investigate the distribution of candidate genes in 
healthy Macedonian and Albanian populations and the 
association of candidate genes with stroke in 
Macedonians and Albanians from the Republic of 
Macedonia. Of these, genetic analyses were 
completed for 141 (66.51%) participants, all of whom 
were Albanians, while others are in progress. The 
present study comprises 39 patients with acute FIS 
treated at the Clinical Hospital Tetovo, Department of 
Neurology as a study group and 102 healthy 
volunteers as a control group. Each individual was 
interviewed on a one-to-one basis, his/her genealogy 
was recorded for the past three generations, and their 
Albanian origin was ascertained by making enquiries 
as far back as their four grandparents. Admixture, if 
any, was recorded for each individual. Individuals with 
only one Albanian parent were excluded from the 
study.
 
  
Blood sampling and processing 
A sample of peripheral vein whole blood (10 
mL) was collected by venipuncture in standard 
collection tubes containing anticoagulant 
ethylenediaminetetraacetic acid (EDTA) in the first 24 
h of admission and then dispensed into two tubes 
(one for complete blood picture and the other for 
extraction of DNA). The first tube was transferred to 
the biochemical laboratory for routine analysis and the 
second tube was separated and referred for genetic 
analysis. 
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DNA extraction, molecular genetic 
screening and storage  
At the Institute of Immunobiology and Human 
Genetics, part of the Faculty of Medicine, Ss Cyril and 
Methodius University of Skopje, Skopje, Republic of 
Macedonia [28-30], genomic DNA was isolated from 
peripheral blood leukocytes by the phenol-chloroform 
extraction method [31] or with BioRobot EZ1 
workstation (QIAGEN) [32]. 
Genetic testing of the candidate genes was 
based on the polymerase chain reaction and reverse 
hybridization principle using the CVD SripAssay 
[ViennaLab (Laboradiagnostica GmbH, Austria)]. The 
DNA samples were subsequently stored in the 
anthropology project field of the Macedonian Human 
DNA Bank (hDNAMKD) [33]. 
  
Statistical analysis 
The population genetics analysis package, 
PyPop, developed by the Biostatistics Core for the 
Workshop [34-36] was used for analysis of the genetic 
data for this report. All analyses were based on 
available data. The results were collected, tabulated 
and statistically analysed by personal computer and 
the commercially available statistical software 
package SPSS version 17 (SPSS Inc. Chicago, 
Illinois, USA). The distribution of gene polymorphism 
frequency was not perfectly normal.
 
Descriptive statistics were used for the 
prevalence of genetic polymorphisms. Between-group 
differences in genotype frequencies were compared 
using a two-by-two contingency table and analysed by 
chi-square analysis with Yates' correction test. 
Pearson P values, crude odds ratios (OR), and Wald's 
95% confidence intervals (CI) were calculated to test 
the associations between mutations/polymorphisms 
and FIS with free statistical calculators 
(http://www.quantitativeskills.com/sisa/statistics/two2hl
p.htm). The level of statistical significance was set at p 
= 0.05. 
 
 
Results 
 
We analysed genetic tests for a total of 141 
participants, divided into two different groups: data for 
39 patients with FIS (mean age: 62.56 years; range: 
44–82 years), and the results of 102 healthy subjects 
(mean age: 48.86 years; range: 27–71 years). 
 
The baseline and demographic characteristics 
of the study participants are presented in Table 1. 
The mean age at first onset FIS was 
significantly higher in the patient groups older than 60 
years than in the age-matched control group, and the 
difference was statistically significant (t = 7.836; p = 
0.000). 
Table 1: Participants included in the study classified by age 
group 
Age Group 
Patients 
 
Controls 
 N % N % 
18–49 2 5.13 44 43.14 
50–59 12 30.77 46 45.10 
60–69 16 41.03 11 10.79 
>70  9 23.08 1 0.98 
Total 39 100 102 100 
Mean ± SD (years) 62.56 ± 8.73 48.86 ± 10.60 
Range 44–82 27–71 
 t = 7.836; p = 0.000 
 
Genotype frequencies were compared 
separately for all vascular gene variations between 
cohorts of patients and controls. The genotype 
distributions in the study and control groups are 
provided in Table 2.  
When genotype frequencies were stratified 
into distribution frequencies, we observed that in most 
cases, higher frequencies of gene mutations were 
detected in the control group than in the patient group. 
The APOE E3/E3 polymorphism was present in only 
one patient, and the fibrinogen beta (-455G>A) 
mutation was not present in any patient, whereas the 
frequencies of heterozygote carriers of factor V 
(Leiden-G1691A; R2-H1299R), PTH, MTHFR-677, 
MTHFR-1298, FXIII, LTA, HPA 1, ACE, PAI-1, eNOS-
T786C and eNOS-G894T were lower in patients than 
in control subjects.  
Heterozygotes for the factor V Leiden 
mutation were more frequent in control healthy 
subjects (8.82%) than in the group of patients with FIS 
(3 or 7.69%). 
The prevalence of heterozygote variants in 
PTH 20210G>A was higher among controls than 
among patients with FIS (6.86% vs. 2.56%, 
respectively). 
Analysis of the study group for the MTHFR 
C677T polymorphism indicated that 15 (38.46%) 
patients were homozygous for the wild-type (CC), 21 
(53.84%) were heterozygous (CT), and the remaining 
3 (7.69%) were homozygous for the mutant allele 
(TT). In the control group of 102 analyzed subjects, 
the following results were obtained: 27 persons 
(26.47%) were homozygous for the wild-type (CC), 55 
individuals (53.92%) were heterozygous for the 
polymorphism (CT), and 20 individuals (19.61%) were 
homozygous for the variant type (TT). 
The prevalence of wild-type homozygotes and 
heterozygotes for the FXIII V34L Leu34 polymorphism 
differed significantly between patients with acute FIS 
and their respective controls. 
In the EPCR gene, we observed a significant 
difference in the distribution of the CC and CG/GG 
genotype groups between the control and patient 
groups. The carriers of the EPCR 4600AG genotype 
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were more frequent in patients with FIS (10 or 
25.64%) than in control healthy subjects (20 or 
19.61%). In contrast, carriers of the EPCR 4678CG 
genotype were more frequent in control healthy 
subjects (50 or 49.02%) than in patients with FIS (18 
or 46.15%), except for carriers of the EPCR 4678GG 
genotype, which were more frequent in patients with 
FIS (16 or 41.03%) than in healthy subjects (24 or 
23.53%).  
Table 2: Genotype frequencies, Pearson`s P-values, odds 
ratios and Wald's 95% confidence intervals in patients with FIS 
and healthy Albanian controls 
Gene and genetic 
variant 
Control group 
(n = 102) (%) 
Study group 
(n = 39) (%) 
Statistical analysis 
OR (95% CI) 
Pearson's 
P-values 
FV 1691G>A (Leiden)  
N 93 (91.18) 36 (92.31) 0.988 (0.886–1.101) 0.829 
HET 9 (8.82) 3 (7.69) 1.147 (0.328–4.018) 0.829 
HOM 0 (0) 0 (0) * * 
FV H1299R     
N 77 (75.49) 32 (82.05) 0.674 (0.265–1.714) 0.405 
HET 25 (24.51) 7 (17.95) 1.484 (0.583–3.777) 0.405 
HOM 0 (0) 0 (0) * * 
PTH 20210G>A     
N 95 (93.14) 38 (97.44) 0.357 (0.042–3.002) 0.324 
HET 7 (6.86) 1 (2.56) 2.800 (0.333–23.533) 0.324 
HOM 0 (0) 0 (0) * * 
MTHFR 677C>T      
CC 27 (26.47) 15 (38.46) 0.567 (0.264–1.258) 0.164 
CT 55 (53.92) 21 (53.84) 0.687 (0.307–1.54) 0.361 
TT 20 (19.61) 3 (7.69) 0.270 (0.069–1.06) 0.051 
MTHFR 1298A>C     
AA 54 (52.94) 18 (46.15) 1.313 (0.626–2.751) 0.471 
AC 44 (43.13) 20 (51.28) 1.388 (0.622–2.909) 0.385 
CC 4 (3.92) 1 (2.56) 0.750 (0.079–7.154) 0.802 
FXIII V34L     
Val/Val 67 (67.68) 17 (45.94) 2.463 (1.139–5.329) 0.020 
Val/Leu 25 (25.25) 13 (35.14) 2.049 (0.871–4.823) 0.097 
Leu/Leu 7 (7.07) 7 (18.92) 3.941 (1.217–12.763) 0.017 
EPCR 4600A>G      
AA 80 (78.43) 29 (74.36) 1.254 (0.531–2.963) 0.606 
AG 20 (19.61) 10 (25.64) 0.798 (0.338–1.884) 0.606 
GG 2 (1.96) 0 (0) * 0.265 
EPCR 4678G>C     
CC 28 (27.45) 5 (12.82) 2.573 (0.914–7.24) 0.066 
CG 50 (49.02) 18 (46.15) 2.016 (0.675–6.017) 0.203 
GG 24 (23.53) 16 (41.03) 3.373 (1.191–11.704) 0.019 
eNOS 786T>C     
N 35 (34.31) 11 (28.21) 0.133 (0.592–2.984) 0.489 
HET 54 (52.94) 20 (51.28) 1.178 (0.504–2.757) 0.705 
HOM 13 (12.75) 8 (20.51) 1.958 (0.645–5.948) 0.232 
eNOS 894G>T      
N 41 (40.20) 14 (35.90) 1.200 (0.559–2.578) 0.639 
HET 52 (50.98) 24 (61.54) 1.352 (0.626–2.937) 0.446 
HOM 9 (8.82) 1 (2.56) 0.325 (0.038–2.803) 0.286 
LTA 804C>A     
N 82 (80.39) 22 (56.41) 2.423 (0.144–5.623) 0.036 
HET 20 (19.61) 13 (33.33) 0.413 (0.178–0.958) 0.036 
HOM 0 (0) 4 (10.26) * * 
HPA-1 a/b     
1a/1a  75 (73.53) 27 (69.23) 1.235 (0.549–2.775) 0.609 
1a/1b  24 (23.53) 11 (28.21) 1.273 (0.551–2.944) 0.572 
1b/1b  3 (2.94) 1 (2.56) 0.926 (0.092–9.287) 1.000 
ACE I/D     
I/I  0 (0) 1 (2.94) * 0.079 
I/D  49 (61.25) 23 (67.65) * 0.098 
D/D  31 (38.75) 10 (29.41) * 0.057 
APO E ɛ2/ɛ3/ɛ4     
E2/E3  1 (1.25) 0 (0) * 0.856 
E3/E3  60 (75.00) 1 * 0.447 
E3/E4  15 (0) 0 (0) * 0.504 
E4/E4  4 (5.0) 0 (0) * 0.690 
PAI-1     
4G/4G  25 (24.51) 11 (28.21) 0.826 (0.36–1.897) 0.653 
4G/5G  53 (51.96) 19 (48.72) 0.815 (0.337–1.968) 0.649 
5G/5G  24 (23.53) 9 (23.08) 0.852 (0.3–2.421) 0.764 
n = absolute number; % = frequency; OR = Odds ratio; CI = Confidence Interval; *, cannot 
be calculated because expected < 5, ² test. 
 
The eNOS mutation frequencies were higher 
in the patient group. There were no significant 
differences in genotype distribution between patient 
and control groups. 
Heterozygotes for the LTA C804A 
polymorphism were more frequent in patients with FIS 
(13 or 33.33%) than in control healthy subjects (20 or 
19.61%).  
HPA-1 1a/1b and ACE I/D mutation 
frequencies were higher in the control than in the 
study group, but the polymorphism frequency was not 
significantly different between the study and control 
groups. 
No homozygous or heterozygous mutants for 
APO B were detected in any of the groups (in all 
patients and controls, the APO-B genotype distribution 
was normal; these data are not shown in Table 2).  
PAI-1, 4G/5G and 5G/5G mutation 
frequencies were higher in the control than in the 
study group, but the polymorphism frequency was not 
significantly different between the study and control 
groups. 
The prevalence of all investigated gene 
variations did not differ significantly between the 
studied groups (Pearson's P value > 0.05), except for 
the prevalence of the homozygous wild-type and 
heterozygous genotypes, FXIII V34L Leu34 carriers 
and homozygotes (GG) for the factor EPCR G4678C 
polymorphism. There were also no significant 
differences with regard to ethnicity (all participants 
were Albanians from the Republic of Macedonia). The 
frequency of ACE I/D carriers was 67.65%, that of 
eNOS-G894T heterozygotes was 61.54% and the 
MTHFR C677T CT genotype was detected in 53.84% 
of patients.  
The most frequent ACE genotype in patients 
with FIS was I/D, with an observed frequency of 
67.65%; a lower frequency was found for the D/D 
genotype (29.41%) and the lowest frequency was 
found for the I/I genotype (2.94%). 
The most frequent PAI-1 genotype in patients 
with FIS was 4G/5G, with an observed frequency of 
48.72%; a lower frequency was found for the 4G/4G 
genotype (28.21%) and the lowest frequency was 
found for the 5G/5G genotype (23.08%). The 
frequencies of the PAI-1 4G/4G and 4G/5G genotypes 
were slightly increased in healthy individuals (24.52% 
and 51.96%, respectively), but that of PAI-1 5G/5G 
was decreased (23.53%). 
 
 
Discussion 
 
Traditionally, the greatest clinical challenge in 
the prevention of ischemic stroke is focused on the 
modification of the main risk factors for 
atherosclerosis, including symptomatic treatment of 
hypertension, diabetes, hypercholesterolemia and 
smoking [10-12]. 
 Kamberi et al. Vascular Genetic Variants and Ischemic Stroke Susceptibility in Albanians 
______________________________________________________________________________________________________________________________ 
_______________________________________________________________________________________________________________________________ 
Open Access Maced J Med Sci.                                                                                                                                                                                                         5 
 
For the first time in the Republic of 
Macedonia, the determination of a heritable 
component to the risk of acute FIS was carried out in 
unrelated cohorts from an Albanian population living in 
the Republic of Macedonia. We performed a genetic 
analysis of patients presenting with ischemic stroke 
that clinically was their first stroke episode and 
community controls who were subsequently included 
in a national project [28-30]. The purpose of this study 
was to investigate the role of specific genes and to 
obtain data that would support an association of gene 
polymorphisms regarding the aetiology of ischemic 
stroke.  
Excluding FXIII Leu34 carriers and 
homozygotes (GG) for the factor EPCR G4678C 
polymorphism, these preliminary results of genetic 
analysis in the present study did not find any 
significant positive (susceptible) association between 
the investigated gene polymorphisms and FIS 
(Pearson's P value greater than 0.05) in this cohort of 
Albanians from the Republic of Macedonia. These 
results are of interest because they differ from those 
of other studies. 
Many of the traditional risk factors that 
increase the risk of ischemic strokes, such as 
hypertension, atrial fibrillation, diabetes mellitus and 
cigarette smoking, are well known and are modifiable 
or avoidable [37]. Genetic risk factors are often 
considered not to be modifiable; however, knowledge 
of genetic risk factors can provide insights into 
pathophysiological pathways and targets for drug 
therapy [10-12]. In the general population and in 
patient cohorts, risk factor profiles change with 
increasing age [38, 39]. Ischemic stroke is the most 
common cerebrovascular disease, and it is often 
attributable to the inherited predisposition, especially 
when apparent at a relatively early age. Approximately 
10% of ischemic strokes occur at ages under 45 years 
[40]. Ischemic stroke is more frequent in women aged 
20–30 years and in men older than 35 years [41]. 
Although many of our patients were middle-
aged or elderly (see Table 1), it is clear that in our 
patient group, the number of elderly participants 
exceeded the number of middle-aged and younger 
patients. However, further research would provide 
clear evidence of the impact of gene polymorphisms 
and their role in the aetiology of ischemic stroke as 
the combined effects of multiple susceptibility genes. 
Heritability seems to have a major role in younger 
stroke patients and patients with a family history of 
stroke [42-48].  
Inconsistent results obtained from various 
authors highlight the genetic role among different 
ethnic groups [49, 50]. In Macedonia [51], FV Leiden 
is more prevalent in Macedonians (6.9%) than in 
Albanians (2.9%), whereas the prevalence of FV 
Leiden was higher in Kosovo (3.4%) [52] than in 
Albania (1.8%) [53]. 
The present study shows that the PTH 
G20210A polymorphism is not important in the case of 
ischemic stroke, similarly to Erten et al. [54]. 
Two meta-analyses, one from individuals of 
European descent [55] and another from those of non-
European descent [48] report an association with a 
modest effect for common variants in the genes for 
coagulation factor V, MTHFR, PTH and ACE. 
The MTHFR C677T mutation has been linked 
to an increased risk for ischemic medical events in a 
recent population study [56]. Studies of some 
populations with certain ethnic backgrounds from 
Asian countries, North America and Europe [57-60] 
and from the Eastern Mediterranean region found that 
the prevalence of the MTHFR C677T polymorphism in 
its homozygous state is variable [61-63].  
An elevated total homocysteine (tHcy) level in 
plasma (hyperhomocysteinemia) is the consequence 
of decreased activity of MTHFR and is associated with 
a slight increase in the risk of thrombosis, whereas the 
common C677T polymorphism in MTHFR has been 
associated with an increased risk of the development 
of different cardiovascular diseases [64], including 
ischemic stroke. 
The population frequencies of MTHFR C677T 
homozygotes vary in the United States from 44.6% in 
Caucasians to 42% of Hispanics and 25.6% African-
Americans [65]. The frequency of the MTHFR C677T 
genotype is often reported to be high in European, 
Asian and Central and South American (10%–32%) 
populations and low in different African populations 
(0–3%) and also to show geographical gradients 
among Chinese Han populations [66]. The frequency 
of the MTHFR C677T genotype is variable in different 
geographic and ethnic groups: 28%–32.8% in Indian 
[67-69] and 12.3% in Chinese populations [70].  
The prevalence of a homozygous gene 
mutation in MTHFR C677T was high in Turkish stroke 
patients [71]. In a study in Tamilians [72] the CT 
genotype was seen in 18.1% and the TT genotype in 
1.38%, whereas the MTHFR A1298C polymorphism 
was more prevalent (47.2%) in a Hungarian study 
[73].  
Previously published studies failed to find an 
association between MTHFR (MTHFR-677 and 
MTHFR-1298) genotypes and haplotypes and plasma 
homocysteine levels in patients with occlusive artery 
disease and deep venous thrombosis [74] or between 
MTHFR (MTHFR-677 and MTHFR-1298) [75] and 
PAI-1 polymorphisms [76] and occlusive artery 
disease or deep venous thrombosis in Macedonians. 
Previous studies in Albanians with ischemic 
stroke also found that elevated plasma homocysteine 
levels (hyperhomocysteinaemia) were associated with 
the presence of MTHFR (MTHFR-677 and MTHFR-
1298) gene polymorphisms [28, 30]. In addition, meat 
with a high fat content and hyperhomocysteinemia are 
not the only causes of acute FIS in the Republic of 
Macedonia [77]. Moreover, MTHFR-677 and MTHFR-
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1298 gene polymorphisms were not associated with 
occurrence rates of FIS [28, 30], but there is no data 
on the Albanian population regarding the PAI-1 gene 
and other susceptibility genes that are involved in the 
development and progression of ischemic stroke and 
their possible association with ischemic stroke. 
Pezzini et al. [78] showed that the risk of 
ischemic stroke increased 3-fold with the presence of 
two or more mutations. Co-occurrence of homozygous 
MTHFR TT and ACE D/D genotypes yielded a highly 
significant moderate risk of leukoaraiosis (ischemic 
white matter demyelination). A synergistic effect of the 
MTHFR TT and ACE D/D genotypes and drinking or 
smoking has been found [79].  
Our results demonstrate that the Factor XIII 
Val34Leu polymorphism influences the occurrence of 
acute FIS, in agreement with one study [12] and in 
contrast to another [13]. In the recent study was 
concluded that significant association of Factor V 
Leiden (G1691A), Factor R2 (A4070G), and 
Prothrombin (G20210A) genetic polymorphism with 
occlusive artery disease or deep venous thrombosis in 
Macedonians was not found [80]. 
Although previous studies demonstrated that 
the PAI-1 4G/4G polymorphism might protect against 
ischemic stroke [14-18], our results show that the 
4G/4G genotype of the PAI-1 gene is less frequent in 
patients with FIS than in controls, similarly to Endler et 
al. [17]. 
We observed a difference in the frequency of 
the ACE I/I, I/D and D/D polymorphisms between 
stroke patients and controls, confirming that 
homozygosity for the ACE D/D polymorphism does 
not confer a higher risk of ischemic stroke [54] than 
the I/D and I/I genotypes. Conversely, other studies 
reported that homozygosity for the ACE D/D 
polymorphism is a strong risk factor for ischemic 
stroke [24, 25].  
Several studies have reported that the HPA-
1b polymorphism is associated with ischemic stroke 
[22, 23]; however, GP 1a (HPA5) is correlated weakly 
with ischemic stroke [43]. In the present study, the 
frequencies of the 1a/1a, 1b/b and 1a/1b genotypes 
differed between stroke patients and controls, 
indicating that the 1b/b genotype is not a risk factor for 
ischemic stroke. 
Results of the present study demonstrated 
that the frequency of the APOE, ɛ2/ɛ3/ɛ43 
polymorphisms were not significantly different 
between stroke patients and controls and support the 
notion that APOE, E3/E3 polymorphisms are not 
associated with ischemic stroke [20, 54]. Excluding 
FXIII Leu34 carriers and homozygotes (GG) for the 
factor EPCR G4678C polymorphism, the preliminary 
results of genetic analysis in the present study did not 
find any significant positive (susceptible) association 
between the investigated gene polymorphisms and 
FIS (Pearson's P value > 0.05) in this cohort of 
Albanians from Macedonia. 
The small number of participants in each 
group limited our power of analysis. Consequently, the 
genotype distribution of the investigated single-
susceptibility polymorphisms was under-represented 
or not present, particularly in the patient group. On the 
other hand, the very weak statistical findings may 
suggest that if we had a large number in each group, 
we could find much stronger associations and 
differences that we missed in this small study 
population. However, in the control group, the single 
susceptibility polymorphisms were present, which 
means that differences between the tested groups are 
probably due to ethnic differences rather than 
recruitment bias. There are possibilities that some 
negative findings might be a consequence of low 
statistical power. Such results have previously been 
reported in studies with certain patient groups that 
were also without genotype distribution of the 
investigated single- susceptibility polymorphisms. 
Larger samples may be needed in order to resolve 
these limitations, validate our results and confirm our 
conclusions, which are our next goals. In this case-
control cohort with FIS, in which many of our patients 
were middle-aged or elderly, the single susceptibility 
polymorphisms with FIS had the lowest prevalence. 
These data emphasise the need for primary and 
secondary prevention measures in middle-aged and 
elderly populations targeting modifiable lifestyle 
vascular risk factors.  
Although previous studies have identified 
susceptibility genes that are involved in the 
development and progression of ischemic stroke [6, 
41, 48, 55, 78], the present study showed that the 
examination of individual variants of FXIII Leu34 and 
homozygotes (GG) for the factor EPCR G4678C 
polymorphism could affect the occurrence of ischemic 
stroke. Other analysed single gene polymorphisms in 
this study do not represent risk factors in the aetiology 
of ischemic stroke in patients. However, some results 
indicate that the ACE I/D, eNOS-G894T heterozygous 
and MTHFR C677T CT genotype combination may 
result in a significantly higher risk of FIS in this 
Albanian population from Macedonia. 
This was the first comprehensive study in an 
Albanian population from the Republic of Macedonia 
to indicate polymorphic variation in the prevalence of 
acute FIS. Mutations in these genes in the percentage 
of patients who have acute FIS have been observed, 
suggesting that their combination might act in a 
synergistic and cumulative manner in this Albanian 
population, the study of which is our next goal and 
should be tested in groups of different ethnic origin. 
In summary, the results of mutant genotype 
frequency analysis in a sample of Albanians from the 
Tetovo region can be used for characterization of the 
current genetic profile of Albanians, anthropological 
comparisons, and association studies with different 
diseases. 
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